Eli Lilly and Company Website

Eli Lilly and Company

NYSE-LLY

Company Overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

  • Name

    Eli Lilly and Company

  • CEO

    —

  • Website

    www.lilly.com

  • Sector

    Pharmaceuticals

  • Year Founded

    1876

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Bulls Say

  • Lilly's strong leadership in weight-loss drugs should drive industry-leading growth with approved drugs and well-positioned next-generation weight-loss drugs in the pipeline.

  • Lilly's cancer drug Verzenio reported strong data in early-stage breast cancer, opening up the strong potential in this multibillion-dollar market.

  • Lilly has launched a new Alzheimer’s drug (Kisunla/donanemab) that could become a major blockbuster, especially since few treatment options exist for the disease.

Bears Say

  • The risks to success for Alzheimer’s drug Kisunla remain high because of bottlenecks in patient diagnosis, required scans and monitoring, and competition.

  • Several of Lilly's next-generation cardiometabolic drugs could lead to cannibalization of current approved Lilly drugs.

  • Competition to weight-loss drug Zepbound could significantly increase over the next three years, from established competitor Novo Nordisk as well as new entrants.

Source: Morningstar Analysis - Nov 07, 2025

What's happening

Nov 15, 2025 - Dec 17, 2025

Eli Lilly and Co Surges Amid Positive Developments Despite Competitive Pressures

  • Eli Lilly's weight-loss drug Mounjaro received a favorable recommendation for use in children with type 2 diabetes from the European Medicines Agency.
  • Goldman Sachs raised its price target on LLY, indicating strong analyst confidence in the company’s growth potential.
  • Insider selling activities have raised concerns about future sales dynamics amid increasing competition in the obesity treatment market.

Over the past month, Eli Lilly and Co (LLY) has experienced a notable increase of 3.6%, significantly outperforming the S&P 500's return of 1.3% by a margin of 2.3%. This upward trend can be attributed to several key developments that positively influenced investor sentiment and stock performance.

On December 15, LLY saw substantial gains following the European Medicines Agency's recommendation for its weight-loss drug Mounjaro for extended use in children with type 2 diabetes. Additionally, positive results from the Phase 3 EMBER-3 trial for Inluriyo in advanced breast cancer further bolstered investor confidence. Goldman Sachs also raised its price target on LLY from $951 to $1,145, reflecting strong analyst optimism regarding the company's growth trajectory.

Earlier in December, news regarding expedited FDA reviews for orforglipron fueled bullish sentiment around LLY’s weight-loss initiatives as it could lead to an earlier decision date than anticipated. Moody’s affirmation of LLY’s Aa3 rating with a positive outlook contributed positively during this timeframe as well.

Despite these bullish indicators, there were bearish sentiments stemming from competitive pressures within the obesity treatment market due to Novo Nordisk adjusting pricing strategies against similar products offered by Eli Lilly. Insider selling activities raised concerns among investors about future sales dynamics amidst increasing competition affecting profitability margins.

Overall, throughout this one-month period marked by significant events impacting both investor confidence and competitive positioning within healthcare sector dynamics, Eli Lilly managed to outperform not only its own historical performance but also outpaced broader market indices like S&P 500 while exceeding sector benchmarks; specifically outperforming Health Care (XLV) sector returns by an impressive margin of 2.2%.

NYSE:LLY